Halozyme Therapeutics (HALO) Tax Provisions (2016 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Tax Provisions of $30.3 million for Q1 2026, up 17.66% year-over-year from $25.7 million in Q1 2025, and down 25.68% quarter-over-quarter from $40.7 million in Q4 2025.
Halozyme Therapeutics (HALO) Tax Provisions (2016 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Tax Provisions for 11 consecutive years, with $30.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Tax Provisions rose 17.66% year-over-year to $30.3 million; the TTM figure through Mar 2026 stood at $154.5 million (up 29.21% YoY), while the FY2025 annual figure was $150.0 million, up 32.68% from the prior year.
- Tax Provisions slipped to $30.3 million in Q1 2026 per HALO's latest filing, from $40.7 million in the prior quarter.
- Across five years, Tax Provisions topped out at $43.7 million in Q3 2025 and bottomed at $7.3 million in Q2 2022.
- Historically, Tax Provisions has averaged $23.9 million across 5 years, with a median of $19.9 million in 2023.
- Annual changes were most pronounced in 2022 — Tax Provisions soared 12531.03% — and 2023, when it fell 11.73%.
- Halozyme Therapeutics' Tax Provisions stood at $13.1 million in 2022, then grew by 20.61% to $15.8 million in 2023, then surged by 160.99% to $41.2 million in 2024, then slipped by 1.12% to $40.7 million in 2025, then declined by 25.68% to $30.3 million in 2026.
- Business Quant data shows HALO's Tax Provisions at $30.3 million in Q1 2026, $40.7 million in Q4 2025, and $43.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 55.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55.00 Mn |
| Mar 31, 2026 | 30.28 Mn |
| Dec 31, 2025 | 40.74 Mn |
| Sep 30, 2025 | 43.70 Mn |
| Jun 30, 2025 | 39.78 Mn |
| Mar 31, 2025 | 25.73 Mn |
| Dec 31, 2024 | 41.20 Mn |
| Sep 30, 2024 | 28.14 Mn |
| Jun 30, 2024 | 24.50 Mn |
| Mar 31, 2024 | 19.21 Mn |
| Dec 31, 2023 | 15.79 Mn |
| Sep 30, 2023 | 19.92 Mn |
| Jun 30, 2023 | 18.40 Mn |
| Mar 31, 2023 | 12.62 Mn |
| Dec 31, 2022 | 13.09 Mn |
| Sep 30, 2022 | 12.07 Mn |
| Jun 30, 2022 | 7.33 Mn |
| Mar 31, 2022 | 14.30 Mn |
| Dec 31, 2021 | -11.96 Mn |
| Sep 30, 2021 | -142.48 Mn |